Early Clinical Predictors of Sustained Disease-Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Glatiramer Acetate and Interferon Beta (PD5.008)

Relapsing Remitting Multiple Sclerosis ◽

Free Status

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

The Lancet Neurology ◽

10.1016/s1474-4422(11)70023-0 ◽

2011 ◽

Vol 10 (4) ◽

pp. 329-337 ◽

Cited By ~ 139

Author(s):

Gavin Giovannoni ◽

Stuart Cook ◽

Kottil Rammohan ◽

Peter Rieckmann ◽

Per Soelberg Sørensen ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Subgroup Analysis ◽

Relapsing Remitting ◽

Post Hoc ◽

Relapsing Remitting Multiple Sclerosis ◽

Free Status

Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosis

10.1002/14651858.cd009333 ◽

2011 ◽

Author(s):

Loredana La Mantia ◽

Alberto Vaona ◽

Marco Rovaris ◽

Francesco Berardo ◽

Serena Frau ◽

...

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis

http://isrctn.org/> ◽

10.1186/isrctn31557558 ◽

2013 ◽

Author(s):

Mike Boggild

Keyword(s):

Multiple Sclerosis ◽

Randomised Controlled Trial ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Controlled Trial ◽

Sequential Treatment ◽

Relapsing Remitting ◽

Randomised Controlled ◽

PNP15: COST-UTILITY ANALYSIS OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE OR INTERFERON BETA IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)64043-0 ◽

2003 ◽

Vol 6 (3) ◽

pp. 277

Author(s):

C Rubio-Terrés ◽

F Medina ◽

I Aristegui ◽

G Izquierdo

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health ◽

10.1016/j.jval.2013.08.1827 ◽

2013 ◽

Vol 16 (7) ◽

pp. A623

Author(s):

J. Darba ◽

L. Kaskens ◽

R.osa R Sánchez-de la

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis

Frontiers in Neurology ◽

10.3389/fneur.2020.00944 ◽

2020 ◽

Vol 11 ◽

Author(s):

Martina Novotna ◽

Ales Tvaroh ◽

Jan Mares

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Interferon Beta ◽

Clinical Disease ◽

Clinical Parameters ◽

Treatment Change ◽

Clinical Disease Activity ◽

Relapsing Remitting ◽

The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing-Remitting Multiple Sclerosis - Clinical Outcomes (PL02.003)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.pl02.003 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. PL02.003-PL02.003 ◽

Cited By ~ 4

Author(s):

F. Lublin ◽

S. Cofield ◽

G. Cutter ◽

R. Conwit ◽

P. Narayana ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Randomized Study ◽

Double Blind ◽

Combined Use ◽

Relapsing Remitting ◽

Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study

Journal of Medical Economics ◽

10.3111/13696998.2014.890936 ◽

2014 ◽

Vol 17 (3) ◽

pp. 215-222 ◽

Cited By ~ 11

Author(s):

Josep Darbà ◽

Lisette Kaskens ◽

Rainel Sánchez-de la Rosa

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

Real-world Propensity Score Comparison of Treatment Effectiveness of Peginterferon beta-1a vs. Subcutaneous Interferon beta-1a, Glatiramer Acetate, and Teriflunomide in Patients with Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2021.102935 ◽

2021 ◽

pp. 102935

Author(s):

Anthony T Reder ◽

Nancy Arndt ◽

Cortnee Roman ◽

Caroline Geremakis ◽

Jason P Mendoza ◽

...

Keyword(s):

Multiple Sclerosis ◽

Propensity Score ◽

Glatiramer Acetate ◽

Real World ◽

Interferon Beta ◽

Treatment Effectiveness ◽

Relapsing Remitting ◽

HF ISSUED+ WITHDRAWN 29/09/06 - THIS ISRCTN90671233 WAS DUPLICATE OF 31557558 - A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis

http://isrctn.org/> ◽

10.1186/isrctn90671233 ◽

2012 ◽

Author(s):

Mike Boggild

Keyword(s):

Multiple Sclerosis ◽

Randomised Controlled Trial ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Controlled Trial ◽

Sequential Treatment ◽

Relapsing Remitting ◽

Randomised Controlled ◽